share_log

Virpax Pharmaceuticals | 8-K: VIRPAX PHARMACEUTICALS REPORTS 2024 SECOND QUARTER RESULTS AND RECENT DEVELOPMENTS

Virpax Pharmaceuticals | 8-K: VIRPAX PHARMACEUTICALS REPORTS 2024 SECOND QUARTER RESULTS AND RECENT DEVELOPMENTS

Virpax制药 | 8-K：VIRPAX PHARMICALS公布2024年第二季度业绩和近期进展
美股sec公告 ·  08/13 07:37
Moomoo AI 已提取核心信息
Virpax Pharmaceuticals, Inc., a Delaware-based company specializing in non-addictive pain management and other pharmaceuticals, reported its financial results for the second quarter ended June 30, 2024, on August 13, 2024. The company announced a decrease in general and administrative expenses to $1.5 million from $1.9 million in the same period the previous year, attributed to reduced severance and insurance expenses. Research and development expenses increased to $2.0 million, up from $1.3 million, mainly due to preclinical activities for their lead asset, Probudur. The operating loss for the quarter was $3.5 million, compared to $3.1 million in 2023. As of June 30, 2024, Virpax had cash reserves of approximately $1.9 million. The company also highlighted recent developments, including positive results from a pharmacokinetics and safety study for Probudur, securing $2.8 million from warrant exercises, and regaining compliance with Nasdaq's minimum bid price requirement. Additionally, Virpax completed a $2.5 million secured loan financing, which led to a reorganization of the company's Board of Directors and the repayment of litigation settlement liabilities.
Virpax Pharmaceuticals, Inc., a Delaware-based company specializing in non-addictive pain management and other pharmaceuticals, reported its financial results for the second quarter ended June 30, 2024, on August 13, 2024. The company announced a decrease in general and administrative expenses to $1.5 million from $1.9 million in the same period the previous year, attributed to reduced severance and insurance expenses. Research and development expenses increased to $2.0 million, up from $1.3 million, mainly due to preclinical activities for their lead asset, Probudur. The operating loss for the quarter was $3.5 million, compared to $3.1 million in 2023. As of June 30, 2024, Virpax had cash reserves of approximately $1.9 million. The company also highlighted recent developments, including positive results from a pharmacokinetics and safety study for Probudur, securing $2.8 million from warrant exercises, and regaining compliance with Nasdaq's minimum bid price requirement. Additionally, Virpax completed a $2.5 million secured loan financing, which led to a reorganization of the company's Board of Directors and the repayment of litigation settlement liabilities.
总部位于特拉华州的Virpax Pharmaceuticals Inc.，是一家专门从事无成瘾性疼痛管理和其他药物的公司。该公司公布了截至2024年6月30日第二季度的财务业绩，报告于2024年8月13日。该公司宣布将总务和管理费用从去年同期的190万美元减少至150万美元，这归因于减少离职补偿和保险费用。研发费用增加到200万美元，较去年同期的130万美元有所增加，主要是由于其主要资产Probudur的临床前活动。本季度的营业亏损为350万美元，相比于2023年的310万美元有所增加。截至2024年6月30日，Virpax的现金储备约为190万美元。该公司还强调了最近的进展，包括Probudur药物的药代动力学和安全性研究的积极结果、从认股权行使中获得280万美元的资金，以及重新符合纳斯达克的最低买盘要求。此外，Virpax完成了250万美元的担保贷款融资，导致公司董事会的重组和诉讼和解责任的偿还。
总部位于特拉华州的Virpax Pharmaceuticals Inc.，是一家专门从事无成瘾性疼痛管理和其他药物的公司。该公司公布了截至2024年6月30日第二季度的财务业绩，报告于2024年8月13日。该公司宣布将总务和管理费用从去年同期的190万美元减少至150万美元，这归因于减少离职补偿和保险费用。研发费用增加到200万美元，较去年同期的130万美元有所增加，主要是由于其主要资产Probudur的临床前活动。本季度的营业亏损为350万美元，相比于2023年的310万美元有所增加。截至2024年6月30日，Virpax的现金储备约为190万美元。该公司还强调了最近的进展，包括Probudur药物的药代动力学和安全性研究的积极结果、从认股权行使中获得280万美元的资金，以及重新符合纳斯达克的最低买盘要求。此外，Virpax完成了250万美元的担保贷款融资，导致公司董事会的重组和诉讼和解责任的偿还。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息